clinical glutathione EuroMedica Clinical Glutathione™ - EuroMedica

The combination of redox buffering and inflammatory damping is a recurring theme across the compound's reported applications

HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF-mutant colorectal cancer by downregulation of c-FLIPL

FEMS Immunol Med Microbiol

My vision is you build a life raft

Key benefits: Brightens skin

Mechanistic Comparison# Dosing Comparison# Amycretin Dosing# Amycretin dosing is investigational: Subcutaneous: Once-weekly injection, doses up to 60 mg studied in phase 1b/2a over 36 weeks Oral: Daily tablet, doses up to 50 mg (or 2 x 50 mg) studied in phase 1 Phase 2 T2D: Both subcutaneous and oral formulations studied over 36 weeks Phase 3 dose selection will be informed by the completed phase 2 data